Gilead CSO, Other Executives, Departing Company as CEO Continues to Reshape C-Suite

ALEX KEOWN | July 17, 2019 | 23 views

Gilead Sciences is seeing a significant change in its executive leadership team as multiple longtime employees are heading out the door as new Chief Executive Officer Daniel O’Day continues to shape the lineup of his lieutenants.

Spotlight

SouthernBiotech

Southern Biotechnology Associates, Inc., now known as SouthernBiotech, was founded in 1982, by scientists from Dr. Max Cooper’s Cellular Immunology Laboratory at the University of Alabama in Birmingham (UAB), as a company dedicated to the production, purification, conjugation and commercialization of the world’s highest quality, affinity purified, secondary antibodies for research use.

OTHER ARTICLES
MEDTECH

Expansion of BioPharma: Opportunities and Investments

Article | July 16, 2022

Biopharmaceutical innovations are among the most ingenious and refined achievements of modern medical science. New concepts, techniques, and therapies are emerging, such as the cell therapy Provenge, which can be used to treat cancer, and gene therapies, which provide even more amazing promises of disease remission and regenerative medicine. In addition, the COVID-19 pandemic has caused a huge boom in the pharmaceutical industry. This is because more and more attention is being paid to increasing manufacturing capacity and starting new research on drug development. Biopharma: Leading the Way in the Pharma Sector In the past couple of years, the biopharmaceutical sector has deepened its roots across the medical and pharmaceutical industries, on account of the transformation of pharmaceutical companies towards biotechnology, creating opportunities for growth. Also, growing advancements in technologies such as 3D bioprinting, biosensors, and gene editing, along with the integration of advanced artificial intelligence and virtual and augmented reality are estimated to further create prospects for growth. According to a study, the biopharmaceutical sector makes nearly $163 billion around the world and grows by more than 8% each year, which is twice as fast as the traditional pharma sector. Massive Investments Directed Towards Biopharma Investing in biotech research and development (R&D) has yielded better returns than the pharma industry average. Hence, a number of pharmaceutical companies are shifting their presence toward biopharma to capitalize on the upcoming opportunities by investing in and expanding their biotechnology infrastructure. For instance, Thermo Fisher Scientific Inc., an American manufacturer of scientific instrumentation, reagents and consumables, and software services, announced an investment of $97 million to expand its bioanalytical laboratory operations into three new locations in the U.S. With this investment, the company will add 150,000 square feet of scientific workspace and install the most advanced drug development technologies to produce life-changing medicines for patients in need.

Read More
MEDTECH

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 12, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
MEDTECH

Biotech in 2022

Article | September 22, 2022

The robust global channel of more than, 800 gene and cell curatives presently in trials will produce clinical readouts in 2022, revealing what lies ahead for advanced curatives. The impact will be felt in 2022, no matter how you slice it. Eventually, how well industry and non-supervisory bodies unite to produce new frameworks for advanced therapies will shape the year 2022 and further. Pacific Northwest talent will continue to contribute to the advancement of gene and cell curatives in both the short and long term, thanks to its deep pool of ground-breaking scientific developers, entrepreneurial directorial leadership, largely skilled translational scientists, and endured bio manufacturing technicians. We may see continued on-life science fund withdrawal from biotech in 2021, but this can be anticipated as a strong comeback in 2022 by biotech industry, backed by deep-pocketed life science investors who are committed to this sector. A similar investment, combined with pharma's cash-heavy coffers, can result in increased junction and acquisition activity, which will be a challenge for some but an occasion for others. Over the last five years, investment interest in Seattle and the Pacific Northwest has grown exponentially, from Vancouver, British Columbia, to Oregon. The region's explosive portfolio of new biotech companies, innovated out of academic centres, demonstrates the region's growing recognition of scientific invention. This created a belief that continued, especially because Seattle's start-ups and biotech enterprises are delivering on their pledge of clinical and patient impact. Talent and staffing will continue to be difficult to find. It's a CEO's market, but many of these funds' return, and are not rising in proportion to the exorbitant prices they're paying to enter deals. This schism has become particularly pronounced in 2021. Hence, everyone in biotech is concerned about reclamation and retention.

Read More
MEDTECH

Next-Gen Genetics Cancer Therapies Creating Investment Prospects

Article | July 5, 2022

Genetic therapeutics such as genetic engineering and gene therapy are increasingly emerging as one of the most influential and transformed biotechnological solutions around the globe in recent times. These genetic solutions are being assessed across various medical domains, including cancer treatment, neurology, oncology, and ophthalmology. Citing the trend, the genetics industry is estimated to experience a tsunami of approvals, with over 1,000 cell and gene therapy clinical trials currently underway and over 900 companies worldwide focusing on these cutting-edge therapies. Growing Cancer Encourages Advancements in Genetic Technologies With the surging cases of cancers such as leukemias, carcinomas, lymphomas, and others, patients worldwide are increasing their spending on adopting novel therapeutic solutions for non-recurring treatment of the disease, such as gene therapy, genetic engineering, T-cell therapy, and gene editing. As per a study by the Fight Cancer Organization, spending on the treatment of cancer increased to $200.7 billion, and the amount is anticipated to exceed $245 billion by the end of 2030. Growing revenue prospects are encouraging biotechnology and biopharmaceutical companies to develop novel genetic solutions for cancer treatment. For instance, Bristol-Myers Squibb K.K., a Japanese pharmaceutical company, introduced a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, Abecma, for the treatment of relapsed or refractory (R/R) multiple myeloma in 2022. Amid a New Market: Genetics Will Attract Massive Investments Despite several developments and technological advancements, genetics is still considered to be in a nascent stage, providing significant prospects for growth to the companies that are already operating in the domain. Genetics solutions such as gene therapies, gene editing, and T-cell immunotherapy are emerging as highly active treatments across various medical fields, resulting in increasing research and development activities across the domain, drawing significant attention from investors. Given the potential of genetic treatments and the focus on finding new ways to treat cancer and other related diseases, it's easy to understand why companies are investing in the domain. For instance, Pfizer has recently announced an investment of around $800 million to construct development facilities supporting gene therapy manufacturing from initial preclinical research through final commercial-scale production. Due to these advancements, cell and gene therapies are forecast to grow from $4 billion annually to more than $45 billion, exhibiting growth at a 63% CAGR. The Future of Genetics Though there is a significant rise in advancement in genetic technologies and developments, the number of approved genetic treatments remains extremely small. However, with gene transfer and CRISPR solutions emerging as new modalities for cancer treatment, the start-up companies will attract a growing amount and proportion of private and public investments. This is expected present a tremendous opportunity for biopharma and biotechnology investors to help fund and benefit from the medical industry's shift from traditional treatments to cutting-edge genetic therapeutics in the coming years.

Read More

Spotlight

SouthernBiotech

Southern Biotechnology Associates, Inc., now known as SouthernBiotech, was founded in 1982, by scientists from Dr. Max Cooper’s Cellular Immunology Laboratory at the University of Alabama in Birmingham (UAB), as a company dedicated to the production, purification, conjugation and commercialization of the world’s highest quality, affinity purified, secondary antibodies for research use.

Related News

Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in 5.1B Dollars R and D Collaboration

Genengnews | July 15, 2019

Gilead Sciences will shell out 5.1 billion dollars to nearly double its minority stake in Galapagos from approximately 12.3% to at least 22% and possibly about 30% through a 10-year global R and D collaboration in which Gilead will expand its role in the companies arthritis candidate filgotinib and co-develop the rest of Galapagos pipeline. “Gilead also gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure,” Gilead Chairman and CEO Daniel O’Day said yesterday in a statement. Galapagos’ pipeline includes six molecules currently in clinical trials, more than 20 preclinical programs, and a drug discovery platform designed to discover and verify novel targets by using disease-related, human primary cell-based assays. In the first major R&D deal under O’Day, who took the company’s helm on March 1, Gilead agreed to pay Galapagos an eye-popping $3.95 billion upfront—more than 12 times the €318 million ($358 million) in revenue generated by Galapagos last year, and 18% of Gilead’s total $22.127 billion in 2018 revenue. Gilead will also make a $1.12 billion equity investment in Galapagos, which will use the proceeds to expand and accelerate its R&D programs, the companies said. The equity investment will consist of a subscription for new Galapagos shares at a price of €140.59 ($158.42) per share, representing a 20% premium to Galapagos’ 30-day, volume-weighted average price.

Read More

Gilead Pledges 2.4 Million Annual Dose Donations of Drug to End HIV in the U.S.

Biospace | May 10, 2019

As part of a national effort from the federal government to combat HIV and prevent future infections, Gilead Sciences announced it will annually donate 2.4 million doses of its HIV treatment Truvada for PrEP to the U.S. Centers for Disease Control and Prevention (CDC) to provide treatment for uninsured Americans. Foster City, Calif.-based Gilead said the donation is among the largest seen in the United States and is part of the company’s ongoing initiative to help ensure that all patients who can benefit from Truvada for PrEP can have access to it. PrEP, which has a list price of $20,000, is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

Read More

Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir

Gilead Sciences | December 08, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or with compensated cirrhosis.

Read More

Gilead Expands Galapagos Stake, Filgotinib Role, Pipeline Access in 5.1B Dollars R and D Collaboration

Genengnews | July 15, 2019

Gilead Sciences will shell out 5.1 billion dollars to nearly double its minority stake in Galapagos from approximately 12.3% to at least 22% and possibly about 30% through a 10-year global R and D collaboration in which Gilead will expand its role in the companies arthritis candidate filgotinib and co-develop the rest of Galapagos pipeline. “Gilead also gains exclusive access to all current and future compounds in Galapagos’ rich pipeline while Galapagos is able to expand its research activities and build commercial infrastructure,” Gilead Chairman and CEO Daniel O’Day said yesterday in a statement. Galapagos’ pipeline includes six molecules currently in clinical trials, more than 20 preclinical programs, and a drug discovery platform designed to discover and verify novel targets by using disease-related, human primary cell-based assays. In the first major R&D deal under O’Day, who took the company’s helm on March 1, Gilead agreed to pay Galapagos an eye-popping $3.95 billion upfront—more than 12 times the €318 million ($358 million) in revenue generated by Galapagos last year, and 18% of Gilead’s total $22.127 billion in 2018 revenue. Gilead will also make a $1.12 billion equity investment in Galapagos, which will use the proceeds to expand and accelerate its R&D programs, the companies said. The equity investment will consist of a subscription for new Galapagos shares at a price of €140.59 ($158.42) per share, representing a 20% premium to Galapagos’ 30-day, volume-weighted average price.

Read More

Gilead Pledges 2.4 Million Annual Dose Donations of Drug to End HIV in the U.S.

Biospace | May 10, 2019

As part of a national effort from the federal government to combat HIV and prevent future infections, Gilead Sciences announced it will annually donate 2.4 million doses of its HIV treatment Truvada for PrEP to the U.S. Centers for Disease Control and Prevention (CDC) to provide treatment for uninsured Americans. Foster City, Calif.-based Gilead said the donation is among the largest seen in the United States and is part of the company’s ongoing initiative to help ensure that all patients who can benefit from Truvada for PrEP can have access to it. PrEP, which has a list price of $20,000, is used to reduce the risk of HIV infection in individuals who are at higher risk for HIV. It has been shown to reduce the risk of new infection by up to 97 percent when taken consistently.

Read More

Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir

Gilead Sciences | December 08, 2016

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing sofosbuvir 400 mg, velpatasvir 100 mg, and voxilaprevir 100 mg (SOF/VEL/VOX) for the treatment of direct-acting antiviral (DAA)-experienced chronic hepatitis C virus (HCV)-infected patients. The data submitted in the NDA support the use of the regimen for 12 weeks in DAA-experienced patients with genotype 1 to 6 HCV infection without cirrhosis or with compensated cirrhosis.

Read More

Events